News & Updates
Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year survival was 72% Excerpt from the Press Release: Excerpt from the Press Release: ST. HELIER, Jersey & SHANGHAI, China & SAN FRANCISCO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company working…
Read More
Trial’s 73% twelve-month overall survival rate in newly diagnosed glioblastoma patients compares favorably to historical benchmark of 60% Results show median progression-free survival of 6.9 months and median overall survival of 15.4 months Treatment led to depletion of immunosuppressive myeloid-derived suppressor cells within the tumor microenvironment, suggesting bavituximab may synergistically combine with checkpoint inhibitors Excerpt…
Read More
The Phase 3 ACTIV-1 Immune Modulators study was sponsored by the National Institutes of Health as part of the ACTIV initiative Orencia was one of two immune modulators that improved survival for people hospitalized with COVID-19 Safety profile of Orencia remained consistent, with no new safety signals reported Excerpt from the Press Release: PRINCETON, N.J.–(BUSINESS…
Read More
Partnership will Enable Accuray to Use Limbus’ Technology to Streamline the Treatment Planning Process and Increase Operational Efficiency Excerpt from the Press Release: SUNNYVALE, Calif. and SASKATCHEWAN, Canada, June 2, 2022 /PRNewswire/ — Accuray Incorporated (NASDAQ: ARAY) and Limbus AI Inc. announced today they are partnering to augment Accuray adaptive radiotherapy capabilities by leveraging Limbus’…
Read More
Excerpt from the Press Release: Lead development candidate SG-5-00455 shows potential to become first in class PAI-1/2 inhibitor that directly targets mucosal healing in patients with inflammatory bowel disease (IBD) BRISBANE, Calif., May 24, 2022 – Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, presented…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 25, 2022 /PRNewswire/ — Harbour BioMed (“HBM”, HKEX: 02142) announced that it has successfully completed the dosing of first patient in phase I trial of B7H4x4-1BB bispecific antibody HBM7008 in Australia. This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary…
Read More
Excerpt from the Press Release: SAN JOSE, Calif., May 24, 2022 /PRNewswire/ — OptraSCAN®, the leading end-to-end digital pathology solution provider, announced its digital pathology scanner OS-SiA has been granted US patent – No 2020/0334814 A1 by the United States Patent and Trademark Office. OS-SiA has inbuilt intelligence to scan, index and analyze pathological samples…
Read More
Excerpt from the Press Release: SANTA CLARA, Calif., May 24, 2022 /PRNewswire/ — Invenio Imaging, the leader in intraoperative fresh tissue imaging, announced today the CE Mark for the NIO Glioma Reveal image analysis module. NIO Glioma Reveal is based on deep learning and allows neurosurgeons to identify areas of cancer infiltration in patients undergoing primary…
Read More Open-Label Trial in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, today announced the first patient has been dosed in an open-label Phase 2 study evaluating ENV-101 (taladegib)…
Read More
Meet with Christopher Kata, Director of Sales & Marketing and the TrialStat Team on June 20th – 22nd! Christopher Kata, Director of Sales & Marketing905 [email protected] When: June 27th – July 1st 2021Where: McCormick Place 2301 S King Dr, Chicago, IL 60616, United StatesRegistration: DIA Global Annual Meeting 2022 It’s hard to believe an entire…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?